---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-064882"
form_type: "8-K"
ticker: "RNLXY"
cik: "0001811115"
company_name: "Renalytix plc"
filed_at: "2024-05-28T23:59:59+00:00"
generated_at: "2026-06-01T08:10:58.016721+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CFO O. James Sterling resigns effective May 24; Joel R. Jung appointed interim CFO

## Summary
- CFO O. James Sterling resigned May 24, 2024; will remain through transition period ending June 10, 2024.
- Board appointed Joel R. Jung as interim CFO effective May 28, 2024; Jung was previously CFO at Minerva Surgical (2020-2024).
- CEO stated company is focused on cost reductions and commercial adoption of KidneyIntelX with FDA approval and reimbursement.
- Resignation did not involve any disagreement with the company; Jung has no material interest in related-party transactions.

## SEC filing metadata
- accession: 0000950170-24-064882
- form_type: 8-K
- ticker: RNLXY
- cik: 0001811115
- company_name: Renalytix plc
- filed_at: 2024-05-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017024064882/0000950170-24-064882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017024064882/rnlx-20240524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-064882
- JSON: https://secwatch.observer/filing/0000950170-24-064882.json
- Plain text: https://secwatch.observer/filing/0000950170-24-064882.txt

## Key facts
- Executive change
  Joel R. Jung was appointed as Interim Chief Financial Officer at Renalytix plc.
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: On May 27, 2024, the board of directors (the “ Board ”) of the Company appointed Joel R. Jung as Interim Chief Financial Officer and designated Mr. Jung as the Company’s principal financial officer and principal accounting officer, effective as of May 28, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017024064882/0000950170-24-064882-index.htm
- Executive change
  O. James Sterling resigned as Chief Financial Officer at Renalytix plc.
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On May 24, 2024, O. James Sterling tendered his resignation from his position as the Chief Financial Officer of Renalytix plc (the “ Company ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017024064882/0000950170-24-064882-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.